We have partnered with Dermata Therapeutics, LLC , a private specialty pharmaceutical company developing innovative prescription drugs for dermatological conditions. We have out-Licensed SIG990 to Dermata Therapeutics for the topical treatment of rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG990 has been cleared by the U.S. Food and Drug Administration (FDA) and SIG990 is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product. Dermalogix will receive milestone payments and royalties on revenues of the product. SIG990 Press release